Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 252-558-1 | CAS number: 35435-21-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Principles of method if other than guideline:
- Recovery period: 15 d
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Trimethoxy(2,4,4-trimethylpentyl)silane
- EC Number:
- 251-995-5
- EC Name:
- Trimethoxy(2,4,4-trimethylpentyl)silane
- Cas Number:
- 34396-03-7
- Molecular formula:
- C11H26O3Si
- IUPAC Name:
- trimethoxy(2,4,4-trimethylpentyl)silane
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Strain: Hoe: WISKf (SPF71)
- Source: Hoechst AG, Pharma-Forschung-Toxikologie; breeding under SPF conditions
- Age at study initiation: 5-6 weeks
- Weight at study initiation: Males: 137-150 g. Females: 137-146 g
- Fasting period before study: No
- Housing: : 5 per Makrolon cage
- Diet (e.g. ad libitum): Ad libitum except during exposure
- Water (e.g. ad libitum): Ad libitum except during exposure
- Acclimation period: No data
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22± 2
- Humidity (%): 50± 20
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- other: Air
- Mass median aerodynamic diameter (MMAD):
- < 6 µm
- Remarks on MMAD:
- MMAD / GSD: Particle size (mean): 99.98% of the particle in 0.3 mg/l group, 99.98% of the particle in 1.5 mg/l group and 99.87% of the particle in 3.0 mg/l group are below 6 µm.
- Details on inhalation exposure:
- Duration of exposure: 6h/d, 5d/w
Exposure: Animals were exposed to the test atmosphere in nose-only inhalation units
Exposure apparatus: The inhalation chamber used in the study were stainless steel/glass cylindrical columns. Each column had a volume of 80 L and consisted of a top assembly with the inlet of the test atmosphere, one rodent tube section and the bottom, the base assembly with the exhaust port.
Method of holding animals in test chamber: Nose only; cylindrical tubes.
Method of conditioning air: Compressed air (4 bar), oil separation filter/absolute filter; to achieve requested air humidity moistened air was feeded directly in the chamber
System of generating particulates/aerosols: The inhalation equipment was designed to expose the animals to a continuous supply of fresh test atmosphere. The test atmosphere was generated by passing test material to special nozzels. The operating pressure was 4 bar.
Temperature, humidity: 20.0 - 23.5°C, 31.5-60.6%
Contineous measurement of CO-, CO2- and O2-concentration during exposure in exposure chamber; CO: 0 ppm; CO2: 3800 - 7900 ppm; O2: 19.8 - 20.6 Vol %
Air flow rate: Air inlet 800 L/h; 1100 L/h exhausted
Method of particle size determination: The particle size distribution was measured using an APS 33 Aerodynamik Particle Sizer from TSI Inc., St Paul.
The aerodynamic diameter range measured with this analyzer covered 0.486 to > 15.4 micrometer.
Measurements were performed daily 30 minutes, 2 and 4 hours respectively after starting the exposure.
After the end of the exposure period, the arithmetic means together with the standard deviations based
on the 3 points in time were calculated using a statistics program.
The statistics program was used further to calculate an overall arithmetic mean for each dose group
based on the arithmetic means for each single day of exposure.
Brief description of analytical method used:
Gravimetric verification of concentrations
Gravimentric measurements were performed using a membrane filter, pore size 0.65 micrometer,
50 mm diameter (sartorius Membranfilter GmbH, Göttingen). The air flow rate was 3 l/min, which
is equivalent to an intake velocity of 1.25 m/sec.
Gravimetric measurements were performed daily in the exposure chambers 30 minutes, 2 and 4 hours respectively after starting the exposure.
Chemical verification of concentrations
Within 60 minutes 31 liter aerosol from the exposure chambers was pumped through 3 gas-washing bottles filled with acetone (PESTANAL, RIEDEL DE HAEN) connected in series and standing in a cool trap. Thereof aliquotes were taken and analysed using a gas chromatograph.
The concentration of isooctyltrimethoxysilane in the exposure chambers was calculated based on the results of the GC and
considering the aerosol- and acetone volumina.
Sampling was performed on day 1, 8, 15, 22 and 27 of the treatment. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Gravimetric verification of concentrations
Gravimentric measurements were performed using a membrane filter, pore size 0.65 micrometer,
50 mm diameter (sartorius Membranfilter GmbH, Göttingen). The air flow rate was 3 l/min, which
is equivalent to an intake velocity of 1.25 m/sec.
Gravimetric measurements were performed daily in the exposure chambers 30 minutes, 2 and 4 hours respectively after starting the exposure.
Chemical verification of concentrations
Within 60 minutes 31 liter aerosol from the exposure chambers was pumped through 3 gas-washing bottles filled with acetone (PESTANAL, RIEDEL DE HAEN) connected in series and standing in a cool trap. Thereof aliquotes were taken and analysed using a gas chromatograph.
The concentration of isooctyltrimethoxysilane in the exposure chambers was calculated based on the results of the GC and
considering the aerosol- and acetone volumina.
Sampling was performed on day 1, 8, 15, 22 and 27 of the treatment. - Duration of treatment / exposure:
- 28 days + 14 days recovery
- Frequency of treatment:
- Five days per week; six hours per day
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.32 mg/L air (analytical)
- Remarks:
- 0.3 mg/L air nominal conc.
- Dose / conc.:
- 1.54 mg/L air (analytical)
- Remarks:
- 1.5 mg/L air nominal conc.
- Dose / conc.:
- 2.89 mg/L air (analytical)
- Remarks:
- 3.0 mg/L nominal conc.
- No. of animals per sex per dose:
- Ten
- Control animals:
- other: Air
- Details on study design:
- - Dose selection rationale: No data
- Rationale for animal assignment (if not random): Random
- Rationale for selecting satellite groups: Five animals of each sex and group were used to assess recovery from treatment-related effects
- Post-exposure recovery period in satellite groups: 15 days
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
DETAILED CLINICAL OBSERVATIONS: Mortality, behavior and general state of health (before and after exposure and during exposure; one time per day during weekend); Neurological disorders, opacity of eyes, damage of oral mucosa, disorder of tooth growth (weekly)
BODY WEIGHT: Yes
- Time schedule for examinations: Before exposure began and then twice per week.
FOOD CONSUMPTION: Yes
- Food consumption for each animal determined: Twice per week.
WATER CONSUMPTION: Yes
- Time schedule for examinations: Once per week.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Weekly
- Dose groups that were examined: all dose groups and control
HAEMATOLOGY: Yes
- Time schedule for collection of blood: One day after the last exposure five animals of each sex, then 15 days after last exposure the remaining five animals of each sex.
- Anaesthetic used for blood collection: No
- Animals fasted: No data
- Parameters checked in table 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of serum: One day after the last exposure five animals of each sex, then 15 days after last exposure the remaining five animals of each sex (Nembutal narcosis).
- Parameter checked in table 1 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: At the end of the exposure period
- Parameters checked in table 1 were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations (neurological disorders): Once per week. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 2)
HISTOPATHOLOGY: Yes (see table 2) - Other examinations:
- None
- Statistics:
- The following parameters have been checked inter-collective concerning statistical significance (p = 0.05) in accordance with internal SOP: body weight, body weight gain; haematology (excluding differential blood count, heinz bodies, reticulocytes); clinical chemistry (excluding bilirubin direct, methemoglobin, g-glutamyltranspeptitase); serum electrophoresis, relative organ weights, pH-value urine.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Following exposure each animal of the high dose group had a staggering gait, which was resolved by the next day. In the mid dose group, animals that showed a lack of coordination following exposure were recovered within two hours after exposure. The low dose and control group animals did not have any clinical signs.
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- On days 1 and 3 males of the high and mid dose group had a slightly increased body weight in comparison to the air control animals. Females of the high dose group had a slightly reduced body weight on day 14 and days 21-31.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Males from high and mid dose groups on days 3-29 and females on days 3-31 had slight reductions in feed intake.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- In high dose males there was an increased water consumption on day 7 until the recovery period. Females of this group had elevated water consumption on days 7-29. In the mid dose group males, water consumption was increased from day 14 until recovery, and in females of this group from day 14-29.
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No effects on the eyes.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Statistically significant effects one day after the end of exposure were as follows: increased albumin in mid dose females, increased alpha globulin in high dose males, decreased alpha globulin in mid and high dose females, increased albumin to globulin ratio in mid dose females. Statistically significant effects 15 days after the end of exposure were as follows: increased albumin in low dose males and high dose males and females, decreased beta globulin in low and high dose males, decreased g1 globulin in low dose male and females and high dose females, and increased albumin to globulin ratio in low and high dose males. However, all values were in the normal range and were not considered to be toxicologically relevant.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Statistically significant effects one day after the end of exposure were as follows: increased albumin in mid dose females, increased alpha globulin in high dose males, decreased alpha globulin in mid and high dose females, increased albumin to globulin ratio in mid dose females. Statistically significant effects 15 days after the end of exposure were as follows: increased albumin in low dose males and high dose males and females, decreased beta globulin in low and high dose males, decreased g1 globulin in low dose male and females and high dose females, and increased albumin to globulin ratio in low and high dose males. However, all values were in the normal range and were not considered to be toxicologically relevant.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related effects.
- Behaviour (functional findings):
- not examined
- Description (incidence and severity):
- Not examined but there were no neurological disorders observed in the clinical observations.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were statistically significant increases in lung weight in mid dose males one day after exposure, and lung weight in high dose females 15 days after exposure. However, all values were within the normal range, and there were no corresponding histopathological findings.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related macroscopic changes identified.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- There were no findings in the control, low and mid dose groups. In the high dose group three males and one female had signs of minimal irritation in the alveoli (isolated and small clusters of foam cells). There were no other treatment-related effects.
- Histopathological findings: neoplastic:
- not examined
Effect levels
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- >= 3 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Only minor and reversible effects have been observed at 3 mg/l.
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- In the 28-day inhalation repeated dose toxicity study with triethoxy(2,4,4-trimethylpentyl)silane, conducted according to OECD Test Guideline 412 and in compliance with GLP, the NOAEL for systemic toxicity was concluded to be at least 3 mg/l (nominal) based no adverse systemic effects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.